menu
    • menu
    [{"orgOrder":0,"company":"Exacis Biotherapeutics","sponsor":"Eterna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"ExaNK","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Exacis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exacis Biotherapeutics \/ Exacis Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Exacis Biotherapeutics \/ Exacis Biotherapeutics"},{"orgOrder":0,"company":"Exacis Biotherapeutics","sponsor":"Eterna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Exacis Biotherapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Exacis Biotherapeutics \/ Eterna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Exacis Biotherapeutics \/ Eterna Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Exacis Biotherapeutics

    Menu

    Exacis Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Exacis Biotherapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Exacis Biotherapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Eterna Therapeutics

                            Deal Size : $49.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

                            Details : The acquisition includes global immuno-oncology platform of Exacis and its entire pipeline of engineered cell therapy programs for hematologic and solid tumors. Eterna will produce an unlimited number of mRNA-engineered NK and T-cell therapies derived fr...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Eterna Therapeutics

                            Deal Size : $49.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Exacis Biotherapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Exacis Biotherapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ExaNK

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Eterna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Exacis Biotherapeutics Grants Eterna Therapeutics An Option To License Up To Four Allogeneic Ipsc-Derived Nk A...

                            Details : The opportunity to partner with Exacis and add next-generation mRNA-based NK (ExaNK) and T cell therapies to oncology portfolio is an important step in advancing Eterna’s mission to realize the potential of cell engineering to provide patients with new...

                            Product Name : ExaNK

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : ExaNK

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Eterna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth